期刊文献+

47例深部真菌感染的诊疗经验

Treatment of 47 cases of invasive fungai infection
下载PDF
导出
摘要 目的:通过47例深部真菌感染病例的临床分析,总结该类疾病的特点、诊疗难点和经验。方法:统计整理全组病例的原发病、感染真菌的类型和疗效、总结其经验。结果:本组深部真菌感染中,中老年人占多数(89.4%),且绝大多数(93.61%)以继发性感染的形式出现。真菌菌型分布,白色念株菌仍占主导地位(78.7%)。治疗的关键除得力的抗真菌外,与原发病的治疗密切相关。结论:深部真菌感染的发生与原发病治疗的失当和病人的体弱、免疫力下降有关。治疗上要标本兼顾,尤其对原发病的及时有效治疗起重要作用。原发病类型与真菌感染的种类没有相关性,分布较散,但是要注意八种真菌易感情况。二性霉素B能否在合并肾功能障碍病人中应用要视病因而定:若肾功能障碍主要是由真菌性脓毒症引起的或者说真菌感染是发生肾衰的重要原因之一,可以在监测下有控制使用;如若肾衰与真菌感染无关,则不用为妥。 Objective:To investigate the characteristic,diagnosis and therapy of invasive fungal infections. Methods:Retrospective analysis of recent clinical data of 47 cases of invasive fungal infections in our ICU was per- formed,including primary diseases,specific pathogens,essential managements,and treatment result.Results:A- mong these patients,89.4% of them were elderly individuals,and 93.6 of them were secondary infection.Candida albicans remained the most common pathogens(78.7%)in these patients.In addition to appropriate antifungal treatment,proper management of the primary diseases was also very important to obtain satisfactory outcomes from these infections.Conclusion:The occurrence of invasive fungal infections is usually due to unsuccessful treat- ment of the primary diseases,patients' poor general condition with suppression of immune functions.Therapeutic strategies include elimination of all the risk factors and timely and efficient treatment of the primary diseases.Am- photericin B might he a optimal in spite of to renal dysfunction if it is the result of invasive fungal infection.Other- wise amphotericin B should be avoided in patients with renal dysfunction.
出处 《感染.炎症.修复》 2005年第2期75-77,共3页 Infection Inflammation Repair
关键词 真菌 感染 Fungus Infection
  • 相关文献

参考文献6

二级参考文献15

  • 1王越,宁德俄,郑明新.我院四年间抗菌药物的临床应用及合理评价[J].中国医院药学杂志,1995,15(8):347-348. 被引量:10
  • 2杜斌,陈德昌,刘大为,徐英春,谢秀丽,陈民钧.综合性加强医疗病房的获得性细菌感染[J].中华医学杂志,1996,76(4):262-266. 被引量:39
  • 3张新萍,王永铭,陈斌艳.心血管药物不良反应监测与分析[J].中国药学杂志,1996,31(2):90-92. 被引量:1
  • 4张加芳 韩群芬.院内感染的发生,细菌耐药性及治疗效果与医院抗菌药物使用规划[J].药物流行病学杂志,1997,6(2):95-95.
  • 5[1]Denning DW. Munoz P. Advances in invasive fungal infection and antifungal therapy: introduction[J]. Clin Microbiol Infect 2001,7:(suppl2) Ⅵ
  • 6[2]Pfaller MA, Diekema DJ, Messer SA, et al. Activities of fluconazole and voriconazole against 1586 recent clinical isolates of candida species determined by broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS global antifungal susceptibility program, 2001[J]. J Clin Microbiol, 2003, 41: 1440-1446
  • 7张加芳,药物流行病学杂志,1997年,6卷,2期,95页
  • 8Louie A,Antimicrob Agents Chemother,1999年,43卷,2831页
  • 9Costa SF, Marinho I, Aroujo EA, et al. Nosocomial fungaemia: a 2-year prospective study. J Hosp Infect, 2000, 45 (1): 69-72.
  • 10Nucci M, Biasali 1, Akiti T, et al. A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for nettropenic patients. Clin Infect Dis, 2000, 30(2): 300-305.

共引文献207

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部